Scotia Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Scotia Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,164	Closed	-$232K	–	957
2026 Q1	$232K	Buy	+1,164	New	+$230K	﹤0.01%	826

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Scotia Capital's LGND Position: Q2 2026 in Review

Scotia Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 1,164 shares — an estimated $232K sold.

Scotia Capital first reported a position in LGND in Q1 2026 and held it in 1 quarter. The position peaked at $232K in Q1 2026. 415 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Scotia Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Scotia Capital sold 1,164 Ligand Pharmaceuticals shares in Q2 2026, an estimated $232K.
Scotia Capital first reported a position in Ligand Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Scotia Capital's Ligand Pharmaceuticals position peaked at $232K in Q1 2026.
415 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.